Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

SMC approves bulevirtide for treatment of chronic HDV infection in Scottish patients

Gilead Sciences has announced that the Scottish Medicines Consortium (SMC) has become the first UK health authority to permit routine NHS use of Hepcludex  (bulevirtide) for the treatment of chronic hepatitis delta virus (HDV) infection.

Bulevirtide has been accepted for restricted use within NHS Scotland for the treatment of chronic HDV infection in adult patients with evidence of significant fibrosis, whose disease has responded inadequately to interferon-based therapy or who are ineligible to receive interferon-based therapy due to intolerance or contra-indication.


John Dillon, Professor of Hepatology and Gastroenterology at the University of Dundee said, “Hepatitis delta virus may be less well known that hepatitis B or C, but it is a very aggressive form of viral hepatitis and chronic infection carries potentially life-threatening consequences. However, to date, there have been severely limited treatment options for those affected. The SMC’s recommendation of bulevirtide is therefore welcome news and marks a pivotal step forward for viral hepatitis care in Scotland.”

HDV is caused by the hepatitis delta virus, which requires the hepatitis beta virus (HBV) in order to replicate. Chronic HDV infection has the highest mortality rate of any of the viral hepatitis’ and is thought to affect millions of people across the globe.

Bulevirtide provides a treatment option for patients that, following appropriate training, can be self-administered at home with a once-daily injection. The conditional marketing authorization was granted based on the results of two-Phase II studies, MYR202 and MYR 203. Additional efficacy and safety data from the ongoing MYR301 Phase III study were presented at the EASL conference in 2022.

Commenting on the SMC’s recommendation, Dr Véronique Walsh, Vice President and General Manager, Gilead Sciences UK & Ireland said, “For years, chronic hepatitis delta virus infection has proven to be a notoriously difficult challenge to treat, with no licensed therapy options in the UK. Recommendation is a vitally important turning point, providing the option of bulevirtide across the NHS in Scotland. Gilead remains committed to helping all those who are impacted by viral hepatitis, and this is another important milestone on this journey.”

The SMC’s recommendation is the first of its kind in the UK. A decision from the National Institute of Health and Care Excellence (NICE), which will provide guidance on its use across the rest of the UK, is scheduled to be made in the near future.

More For You

Community Pharmacy England (CPE) chief executive Janet Morrison was one of the signatories of the statement

Community Pharmacy England (CPE) chief executive Janet Morrison was one of the signatories of the statement

Primary care leaders join forces in effort to 'transform investment into primary care'

Community Pharmacy England (CPE) has teamed up with other national primary care bodies to urge the government to allocate more funds towards the sector.

In a joint statement released on the back of the government’s spending review, last week, the organisations welcomed the government’s continued determination to ‘shift care from hospitals to community and from sickness to prevention’ but warned that this would not be possible ‘without further investment in primary care’.

Keep ReadingShow less
Cancer patients warned against using weight-loss jabs

Macmillan Cancer Support said there is not enough evidence on how the weight-loss jabs might affect anti-cancer treatments.

iStock

Cancer patients warned against using weight-loss jabs

Cancer patients have been advised to consult their doctor before taking any weight-loss jabs.

Macmillan Cancer Support has issued this advisory following a surge in calls by cancer patients asking whether they can take fat loss jabs such as Wegovy and Mounjaro.

Keep ReadingShow less
Kamson Pharmacy to deliver more clinical services after installing hub and spoke technology

The FLOWRx auto hub in the new Kamson warehouse in Uckfield.

Kamson Pharmacy to deliver more clinical services after installing hub and spoke technology


Kamsons Pharmacy has announced that it has implemented a state-of-the-art hub and spoke dispensing model with the aim of freeing up more time to deliver clinical services.

Keep ReadingShow less
RPS group aims to tackle barriers holding back black pharmacy students

Work is underway to improve inclusivity in teaching

Pic credit: iStock

RPS group aims to tackle barriers holding back black pharmacy students

A cross-sector group aimed at tackling barriers that block the progression of black students and trainee pharmacists held its first meeting this week.

The Royal Pharmaceutical Society (RPS) has created the Differential Attainment Oversight Group to address issues that black or black British African student pharmacists and foundation trainees face such as limited access to work experience, financial support and visible role models in education and training.

Keep ReadingShow less
Older adult organizing medicine bottles in a cool, dry storage area during warm weather.

People are being advised to keep medicine below 25° C

Pic credit: iStock

Pharmacies advise patients on storing medicines safely during heatwave

Patients are being given important advice and guidance on the impact heat can have on their medicine and where to keep different medicines as the UK goes through a heatwave.

People are being advised to keep medicine below 25° C if they are able to, unless storage instructions state it needs to be kept at an alternative temperature, such as drugs that need to be refrigerated.

Keep ReadingShow less